Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,753.20
(
-1.57%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,041.51
(
-3.92%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 139920

Tuesday, 04/10/2012 12:01:20 PM

Tuesday, April 10, 2012 12:01:20 PM

Post# of 257257
AMGN acquires KAI Pharmaceuticals (private) for $315M in cash:

http://finance.yahoo.com/news/amgen-acquire-privately-held-kai-124500048.html

KAI's lead product candidate, KAI-4169, is a novel agent [in phase-2] being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis… Amgen will acquire worldwide rights, excluding Japan, to KAI-4169.

AMGN evidently likes this program enough to move expeditiously: they are loaning KAI the money to begin phase-3 trials prior to the formal closing of the acquisition.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now